MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. MyMD's presentation video will be available for viewing on demand starting at 7:00 am ET on Monday, September 13th, and management will be available for one-on-one meetings with investors upon request

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders Associated with Chronic Inflammation.” The '933 patent becomes the thirteenth patent protecting the Company's lead cand

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.” The patent protects the Company's drug candidate Supe

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

Oramed Pharmaceuticals

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in addition

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announces that a human cell research study of its lead compound MYMD-1 found the drug to effectively suppress the cytokine storm, a major cause of severity and death in COVID-19 patients. Cytokine storm causes an overreaction of the immune system that can cause the body to attack its tissues and organs, leading to a high proportion of deaths from COVID-19.

MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine Storm

BALTIMORE, Md.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine storm, a major cause of severity and death in COVID-19 patients. Accumulating evidence suggests that an increased level of

MyMD Pharmaceuticals' Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced data from a comparative study conducted by Eurofins Discovery showing commonality between its lead clinical compound MYMD-1 and three FDA-approved JAK inhibitor drugs for the treatment of autoimmune and inflammatory diseases. Janus Kinases (JAKs) are en

MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery (ERF.FP) Phenotypic Center of Excellence (“Eurofins”) comparing the biological activities of MyMD's lead compound MYMD-1, with leading FDA approved TNF inhibitors (TNFi). MYMD-1 is being developed to treat autoimmune and age-relate

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. Membership in the Russell Microcap® Index, which remains in place for one ye

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. “I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms,” stated David Rini. David Rini is a Professor at the

MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced it will host a conference call at 4:15 p.m. Eastern time on Monday, May 17th to provide an update on its clinical and drug development plan. To participate in the briefing session, please click on the link below to register. Questions can be submitted in advance via the contact inform

MyMD Pharmaceuticals Schedules Business Update Conference Call

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company's compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol (CBD) d

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals' Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for application no. 16/612,472, entitled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.” The allowed claims cover the new molecular entity Supe

MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds

MyMD Pharmaceuticals (MYMD) stock is among the biggest movers today with shares soaring just one day after the company's IPO. The post MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Know as Shares Surge appeared first on InvestorPlace.

MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Know as Shares Surge

News for MyMD Pharmaceuticals Stock (MYMD)